Events
ELRIG CRISPR in Drug Discovery 2019
ELRIG CRISPR in Drug Discovery 2019

Dates: 27-28 February 2019
Venue: Oxford, UK

The inaugural ELRIG CRISPR in Drug Discovery:

From Targets to Therapeutics meeting will be held at the King’s Centre, Oxford 27 & 28 February 2019. Genome Engineering, including Zinc-finger, TALEN and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, target validation in developing advanced cellular and in vivo disease models, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus.

We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech, and CROs to hear talks given by speakers at the cutting edge of genome engineering, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

The scientific program for this CRISPR in Drug Discovery meeting will include:

- Large-scale CRISPR functional genomics studies for drug target identification and validation
- Application of genome engineering in developing biological models of disease from single cell through to complex in vitro tissue systems and in vivo models .
- Cutting edge CRISPR genome engineering technologies and their emerging applications
- A perspective from technology leaders toward the future therapeutic applications of genome engineering

Follow the link below for more information:

https://elrig.org/portfolio/2019-genome-engineering-in-drug-discovery-2019-from-targets-to-therapeutics/